Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Segment Information (Tables)

v3.5.0.2
Note 3 - Segment Information (Tables)
 3 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Quarter Ended
 
 
 
September 30,
 
 
 
2016
 
 
2015
 
Net sales
                
Biotechnology
   $ 86,787     $ 75,743  
Diagnostics
     24,233       20,362  
Protein Platforms
     19,573       16,296  
Inter segment
     (12
)
     (20
)
Consolidated net sales
   $ 130,581     $ 112,381  
Segment operating income
                
Biotechnology
   $ 42,480     $ 39,316  
Diagnostics
     6,303       4,711  
Protein Platforms
     209       (1,172
)
Subtotal reportable segments
     48,992       42,855  
Cost recognized on sale of acquired inventory
     (4,221
)
     (1,112
)
Amortization of acquisition related intangible assets
     (10,188
)
     (7,411
)
Acquisition related expenses
     (4,369
)
     (301
)
Stock-based compensation
     (3,190
)
     (2,038
)
Corporate general and administrative
     (1,582
)
     (965
)
Consolidated operating income
   $ 25,442     $ 31,028